RT Journal Article SR Electronic T1 Assesment of long-term omalizumab treatment in severe allergic asthma JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P225 VO 40 IS Suppl 56 A1 Eylem Sercan Özgür A1 Cengiz Özge A1 Ahmet Ilvan A1 Sibel Atis Nayci YR 2012 UL http://erj.ersjournals.com/content/40/Suppl_56/P225.abstract AB Objectives: Several clinical studies have demonstrated omalizumab efficacy in patients with severe allergic asthma, but the treatment period has always been relatively short (4-12 months). There are a few data long term omalizumab therapy. We aimed to assess the long-term clinical and functional effectiveness of the omalizumab treatment in severe allergic asthmatic patients.Methods: Medical registries were used to evaluate the 0, 4, 12 and 36 months effectiveness of omalizumab treatment. 26 patients (female/male:21/5) with severe allergic asthma, uncontrolled despite GINA Step 4 therapy. Effectiveness outcomes included spirometry, level of asthma control which evaluated by asthma control test (ACT), systemic glucocorticosteroid (sGCS) use, emergency room (ER) visits and hospitalizations for severe exacerbations.Results: The mean age was 47.6±13.9 and duration of allergic asthma 22.7±10.1 years. Total IgE serum levels was 322.0±178.1 IU/mL. Mean duration of omalizumab treatment was 40.8±8.2 months. FEV1 improved statistically significant at all time points versus baseline (p<0.05). The level of asthma control as evaluated by ACT was significantly improved after treatment (p<0.05). We determined significant reduce numbers of exacerbation (p<0.05), emergency visits (p<0.05), hospitalizations (p<0.05), sGCS (p<0.05) and SABA (p<0.05) use at 36 months.Conclusion: This study showed that long-term therapy with omalizumab for up to 3 years was well tolerated with significant improvement of both symptoms and function. For this reason, suggesting that administration of omalizumab for longer than 12 months could be beneficial for responders patients.